
Annual report 2025
added 02-13-2026
Inspire Medical Systems EBITDA 2011-2026 | INSP
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Inspire Medical Systems
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.9 M | 42.6 M | -37.4 M | -45.7 M | -38.6 M | -55.4 M | -34.4 M | -20 M | -15.7 M | -17.2 M | -19.7 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64.9 M | -55.4 M | -16 M |
Quarterly EBITDA Inspire Medical Systems
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.3 M | 84 K | 1.56 M | - | 16.2 M | 6.5 M | -14.4 M | - | -12.7 M | -15.9 M | -18.9 M | - | -16.7 M | -13.6 M | -15.7 M | - | -8.92 M | -12.2 M | -15.5 M | - | -9.3 M | -22.4 M | -16.3 M | - | -8.31 M | -7.97 M | -8.67 M | - | -4.36 M | -5.45 M | -5.1 M | - | -3.48 M | -4.28 M | -4.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.2 M | -22.4 M | -7.65 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.17 | -2.25 % | $ 1.32 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 17.55 | 2.51 % | $ 412 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
LENSAR
LNSR
|
-21 M | $ 5.27 | -2.14 % | $ 63 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Orthofix Medical
OFIX
|
-4.11 M | $ 12.25 | 0.49 % | $ 485 M | ||
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 7.69 | 9.94 % | $ 1.15 B | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 4.2 | 16.83 % | $ 157 M | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Insulet Corporation
PODD
|
564 M | $ 162.24 | 7.25 % | $ 11.4 B | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.44 | 1.87 % | $ 6.77 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 11.68 | 1.83 % | $ 331 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Stryker Corporation
SYK
|
6.46 B | $ 297.58 | 1.8 % | $ 114 B | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.59 | 2.63 % | $ 36.7 M | ||
|
LivaNova PLC
LIVN
|
228 M | $ 71.08 | 7.28 % | $ 3.88 B | ||
|
Delcath Systems
DCTH
|
898 K | $ 11.28 | 0.18 % | $ 404 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Tandem Diabetes Care
TNDM
|
26 M | $ 18.62 | 3.27 % | $ 1.27 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.04 | - | $ 17.6 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
Myomo
MYO
|
-13.5 M | $ 0.87 | 1.99 % | $ 36.4 M | ||
|
Electromed
ELMD
|
10.7 M | $ 26.74 | 3.06 % | $ 226 M | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.29 | -5.82 % | $ 908 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
757 M | $ 88.97 | -0.29 % | $ 12 B | ||
|
CONMED Corporation
CNMD
|
120 M | $ 37.9 | 1.55 % | $ 1.18 B | ||
|
Varex Imaging Corporation
VREX
|
-4.6 M | $ 12.12 | -0.41 % | $ 502 M | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 88.7 | 2.79 % | $ 3.08 B | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 83.81 | 0.73 % | $ 49 B | ||
|
Tactile Systems Technology
TCMD
|
35.9 M | $ 26.63 | 5.26 % | $ 609 M |